Table 3.

LDL-C Lowering after PCSK9 Inhibitor Therapy
	% Change after 3rd injection	% Change after 6 months	% Change after 1 year
Alirocumab 75mg
Median (IQR)	−52% (−39, −62)	−59% (−47, −72)	−56% (−46, −68)
Alirocumab 150mg
Median (IQR)	−49% (−46, −57)	−55% (−40, −72)	−53% (−44, −68)
Evolocumab 140mg
Median (IQR)	−65% (−50, −78)	−64% (−49, −78)	−61% (−54, −67)
Overall
Median (IQR)	−57% (−45, −71)	−61% (−48, −75)	−60% (−48, −75)
Lipoprotein (a) Lowering after PCSK9 Inhibitor Therapy
	% Change after 3rd injection	% Change after 6 months	% Change after 1 year
Alirocumab 75mg
Median (IQR)	−12% (0, −27)	−23% (−12, −40)	−25% (−13, −39)
Alirocumab 150mg
Median (IQR)	−12% (−9, −16)	−15% (−9, −21)	−18% (−12, −25)
Evolocumab 140mg
Median (IQR)	−14% (0, −31)	−25% (−11, −43)	−18% (0, −35)
Overall
Median (IQR)	−13% (0, −29)	−23% (−10, −38)	−23% (−9, −38)

Patients were excluded from this analysis if they changed from one PCSK9 inhibitor to another

IQR = interquartile range